New York, NY -- (SBWIRE) -- 01/08/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Hercules Offshore, Inc (NASDAQ:HERO), Arena Pharmaceuticals, Inc (NASDAQ:ARNA), USA Technologies, Inc (NASDAQ:USAT), Chelsea Therapeutics International Ltd (NASDAQ:CHTP)
Hercules Offshore, Inc (NASDAQ:HERO) showed a volume of 3.47 million shares by the end of last trade whereas the average volume of the stock remained 2.58 million shares. The stock opened the session at $6.52 but then moved to $6.32. At that price, the stock showed a negative performance of -2.32%. Hercules Offshore, Inc. (Hercules Offshore) provides shallow-water drilling and marine services to the oil and natural gas exploration and production industry globally. It provides these services to national oil and gas companies, integrated energy companies and independent oil and natural gas operators. As of February 23, 2012, it owned a fleet of 42 jackup rigs, 17 barge rigs, two submersible rigs, one platform rig, 58 liftboat vessels and operate an additional five liftboat vessels owned by a third party.
Will HERO Get Buyers Even After The Recent Rally? Find Out Here
Arena Pharmaceuticals, Inc (NASDAQ:ARNA) opened the session at $5.85 and closed the session at $5.83. The stock showed a negative performance of -0.34% in previous trading session. Arena Pharmaceuticals, Inc. (Arena) is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors. Its wholly owned subsidiary, Arena Pharmaceuticals GmbH (Arena GmbH), has granted Eisai Inc., rights to commercialize BELVIQ in the United States. The Company’s oral drug candidates include APD811, an agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension,
Has ARNA Found The Bottom And Ready To Gain Momentum? Find Out Here
USA Technologies, Inc (NASDAQ:USAT) opened the session at $2.20 and closed the session at $2.25. The stock showed a positive performance of 8.22% in previous trading session. The beta of the stock remained 2.65. USA Technologies, Inc. is a provider of technology-enabled solutions that facilitate electronic payment transactions and value-added services primarily within the unattended Point of Sale (POS) market. The Company is a provider in the small ticket, beverage and food vending industry. The Company has designed and marketed systems and solutions that facilitate electronic payment options, as well as telemetry and machine-to-machine (M2M) services, which include the ability to remotely monitor, control,
Why Should Investors Buy USAT After The Recent Gain? Just Go Here and Find Out
Chelsea Therapeutics International Ltd (NASDAQ:CHTP) the stock decreased -3.79% and finished the session at $3.30. Traded with volume of 3.31 million shares in the prior session and the average volume of the stock remained 1.83 million shares. Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases. The Company is developing a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), associated with primary autonomic failure and falls related to NOH in Parkinson’s Disease (PD), as well as other norepinephrine-related conditions and diseases,
Will CHTP Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)